SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SQNM Analysis & Videos »
SQNM: Bull or Bear?
EXACT Sciences Forms Pact with Genzyme
SQNM
|
|
|
+86.44%
in
300 days
EXACT Sciences Forms Pact with Genzyme After the market close, EXACT Sciences announced that it formed a strategic pact with Genzyme (GENZ), which represents the grounds for the Board's refusal two weeks ago in response to Sequenom's (SQNM) hostile exchange offer at $1.50 per share in stock. The announcement followed news in the pre-market today that SQNM planned to commence its exchange offer through 3/24/09, valuing EXAS at $41M. <> However, the GENZ deal included the pur...
|
Create Your Own Diagnostics ETF
SQNM
|
|
|
-5.76%
in
8 days
(closed on 01/28/09)
Create Your Own Diagnostics ETF <> With HealthShares closing shop at year-end , including the former Diagnostics fund, investors who are interested in the space can create their own ETF comprised of companies from the ETF Innovators Preventive Medicine and Emerging Diagnostics Indexes. Below is a list of companies which have stocks listed for trading in the U.S. at over $1/share with a market cap of less than $10B, focusing on smaller companies which are more leveraged to diagnostics and represent possible takeover targets for larger players such as Roche (...
|
A New Global Healthcare Composite Index
SQNM
|
|
|
+5.65%
in
7 days
(closed on 01/20/09)
<> <> <> 
The accompanying table [click to enlarge] presents the top five rated companies with market caps of at least $100M from each of the eight new ETF Innovators healthcare indexes, including a database exceeding 500 companies worldwide. The Healthcare Composite Index is a dynamic, semi-active index with quarterly rebalancing which consists of the 40 top-rated companies on an equal weight basis from each of the eight global healthcare indexes listed below and represents an alternative strategy to existing health composi...
|
EXACT Sciences Rejects Sequenom's $41M Offer
SQNM
|
|
|
-5.17%
in
19 hours
(closed on 01/13/09)
<> Since I profiled EXACT Sciences (EXAS) in late December as part of the ETF Innovators Emerging Diagnostics Index , EXAS announced that its stool-based DNA [sDNA] screening test was added to the colorectal cancer screening options in 12 more states + Washington DC and the Company received an unsolicited, all-stock buyout offer from Sequenom (SQNM) after the market close on Friday, which is valued at $41M or $1.50 per share.
It has not been an easy ride for EXAS since I first wrote about the Company in October 2007, ...
|
A Calendar of Expected Clinical Trial Results
SQNM
|
|
|
-4.55%
in
1 day
(closed on 01/12/09)
<> 
The accompanying table [click to enlarge] includes 58 entries of expected clinical trial results in addition to pending FDA applications for new product approvals + a list of companies which will be required to re-submit their applications due to complete response letters from the agency.
See my recent article on 20 emerging healthcare stocks to watch in 2009 for more details on some of the companies included in the accompanying calendar, in addition to the following companies with near-term catalysts in...
|
Top Five Rated Preventive Medicine Stocks
SQNM
|
|
|
+18.16%
in
12 days
(closed on 01/11/09)
The table at my website link below presents statistics and the top five rated companies in the ETF Innovators [ETFI] Preventive Medicine Index. The index includes U.S.-listed companies with market caps of $150M-$45B which are engaged in healthcare business segments including diabetes care companies such as Novo Nordisk (NVO), vaccine makers such as Nabi Biopharma (NABI), diagnostics companies such as China Medical (CMED), and lab services companies such as LabCorp (LH). http://www.etfinnovators.com/2008/12/five-top-rated-preventiv... <> <> The Top 40 Rated companies have ou...
|
Have Your Say on Healthcare Reform
SQNM
|
|
|
+20.68%
in
22 days
(closed on 12/29/08)
<> Visit the Change.gov website to submit your ideas on healthcare reform as the new Obama-Biden administration prepares for their inauguration on January 20, 2009. Tom Daschle will serve as Secretary of Health & Human Services and is encouraging the nation to share their healthcare experiences and suggestions to improve and reform healthcare in the U.S.
A key feature of the plan is making health insurance coverage possible for all Americans using the existing network of insurers and providers. The plan relies on tax credits for sm...
|
A New Index of Preventive Medicine Cos.
SQNM
|
|
|
+8.58%
in
3 days
(closed on 12/07/08)
<> 
The accompanying table [click to enlarge] presents statistics and the top 15 rated companies in the ETF Innovators [ETFI] Preventive Medicine Index. The index includes U.S.-listed companies with market caps of $200M-$60B which are engaged in the following healthcare business segments: vaccine makers, diagnostics, lab services, and diabetes care.
The index has outpaced the overall market, Healthcare Sector SPDR (XLV), HealthShares Diagnostics (HHD), and iShares Nasdaq Biotech (IBB) over the past year, posting ...
|
Obama-Care Focused on Preventive Medicine
SQNM
|
|
|
-15.80%
in
29 days
(closed on 12/04/08)
<> 
In addition to bullish outlooks for generic drugs and Health IT , President-Elect Obama's healthcare plan plans to focus on public health initiatives and mandated coverage of preventive services such as cancer screenings. The accompanying table presents statistics and the top five rated companies in the ETFI Preventive Medicine Index, including vaccine makers such as Emergent BioSolutions (EBS), diabetes care companies such as Novo Nordisk (NVO), diagnostic companies such as Sequenom (SQNM) and Myriad Geneti...
|
Sequenom (SQNM) Flying off Positive Investor's Business Daily Mention
SQNM
|
|
|
-86.16%
in
455 days
I assume Sequenom (SQNM) is up nearly 8% as I write this on Friday's Investor's Business Daily mention. The story highlighted the company along with Myriad Genetics (MYGN) which I also have looked at closely and strikes my fancy. Valuation is steep though, and I didn't like the "drug" business part of their company - which they might end up splitting off.
<>A decade after dazzling Wall Street with big promises and slender earnings, biotech firms specializing in genetic research have returned with a vengeance -- and even more big promises and slender earnings.<>Rising powers such as San Diego-b...
|
Bookkeeping: Beginning Stake in Sequenom (SQNM)
SQNM
|
|
|
+5.60%
in
12 days
(closed on 08/25/08)
I've been tracking Sequenom (SQNM) for about a month now as the stock trades between $19-$23; following quite possibly one of the biggest runs I've seen post NASDAQ bubble days. In May this was a $7 stock.
This is a speculative play because there are no earnings and this is not a 2008 play, nor a 2009 play, most likely a 2010 or 2011 play. But this is one unique company and I wanted to start my position today; I have no idea what "fair value" is at this point but the potential in this company is enormous IF things go according to plan. Here is a company description
<>Sequenom Inc., a genetic...
|
Sequenom Inc.
SQNM
|
|
|
-82.27%
in
504 days
Sequenom, Inc., a genetics and molecular diagnostic company, provides genetic analysis products that translate genomic science into solutions for biomedical research, molecular medicine, noninvasive prenatal testing, and livestock and agricultural applications. It offers MassARRAY system, a high performance nucleic acid analysis platform that measures genetic target material and variations. The company offers its MassARRAY system for various DNA analysis applications, including SNP genotyping and allelotyping, quantitative gene expression analysis, quantitative methylation marker analysis, ...
|
Sequenom (SQNM): Shares cycle in bullish 'pennant' formation
SQNM
-75.68%
in
529 days
Filed under: Good news, Technical Analysis, Stocks to Buy Sequenom (NASDAQ: SQNM) makes the MassARRAY system, a nucleic acid analysis platform that identifies and quantifies genetic target materials. The system is composed of electronic analysis equipment, related software and various consumables. It is used in biomedical research, livestock testing, oncology diagnoses, molecular medicine, noninvasive prenatal testing, and infectious disease identification. Customers include clinical research laboratories, biotechnology concerns, and universities. <>The company surprised the Street last week, w...
|
People Bullish on SQNM
People Bearish on SQNM
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on SQNM |
More Resources
|
About Sequenom Inc
- Answers.com
